One Hotel Drive,

Boston,

Massachusetts,

US,

ZIP: 02128

Phone: +16174554188

After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.

The 12th Alzheimer's and Parkinson's Drug Development Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD and PD research from senior biopharma KOLs you won't hear anywhere else, with deep-dive content all the way from early discovery through to late phase trials and approvals.

This April, join 150+ senior industry leaders across discovery, preclinical, biomarker, translational, clinical, and commercial this year from Eli Lilly, Biogen, Eisai, Abbvie, Merck, Michael J. Fox Foundation, Acumen, Vigil Neuroscience, and many more....


URLs:
Tickets: https://go.evvnt.com/2146026-2?pid=1052
Brochure: https://go.evvnt.com/2146026-3?pid=1052

Prices:
Conference + Blood-Based Biomarker Focus Day - Industry Pricing: USD 4297.00,
Conference + Workshop Day - Industry Pricing: USD 4297.00,
Conference Only - Industry Pricing: USD 2999.00,
Conference + Blood-Based Biomarker Focus Day - Service Provider Pricing: USD 5197.00,
Conference + Workshop Day - Service Provider Pricing: USD 5197.00,
Conference Only - Service Provider Pricing: USD 3599.00

Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, Carlos Cruchaga, Professor of Neurogenomics, Washington University School of Medicine in St. Louis, Christopher Reading, Senior Vice President Alzheimer's Programs, BioVie Pharma, David Gray, Chief Science Officer, Vigil Neuroscience, Elena Dale, Head of Biology, Eisai, Elizabeth Evans, Chief Operating Officer and Senior Vice President Research, Vaccinex Inc, Enchi Liu, Senior Vice President Translational Sciences, Tranquis Therapeutics Inc., Eric Siemers, Chief Medical Officer, Acumen Pharmaceuticals, Fiona Elwood, Vice President and Disease Area Stronghold Lead, Neurodegeneration, Janssen, Gosia (Malgorzata) Gonciarz, Vice President Genetic Medicine, Eli Lilly and Co., Han-Joo Kim, Chief Executive Officer, IMNEWRUN, Holly Soares, Vice President and Head of Precision Medicine, Pfizer, Hui Zhang, Executive Director, Eli Lilly and Co., Huong Huynh, Reagan Director of Regulatory Science, Critical Path Institute, Iosif Pediaditakis, Associate Director, Alchemab Therapeutics, Javier Conde, Vancells Director - Product Management, bit.bio, John Hey, Chief Scientific Officer, Alzheon, Julia Bonner, Principal Scientist and Lab Head, Sanofi, Kelly Glajch, Associate Scientific Director, Neurodegenerative Diseases, Biogen, Kira Holmstrom, Head of Biomarker Research, Herantis Pharma, Kiran Yanamandra, Principal Scientist, Abbvie, Kirk Brown, Vice President, Research, Alnylam Pharmaceuticals, Krishna Subramanian, Vice President, Head of Non-Clinical and Translational Science, Seelos Therapeutics Inc., Kuti Baruch, Vice President R and D, Immunobrain, Laura Cohen, Associate Vice President, Alzheimer's Environment Shaping, Eli Lilly and Co., Liuqing (Jasmine) Yang, Statistics Manager, Abbvie, Mark Shearman, Chief Executive Officer, Aprinoia Therapeutics Inc., Mathias Schmidt, President and Chief Executive Officer, Senior Executive Director - Global Strategy, JCR USA, Matthew Czech, Associate Director, Digital Science, Abbvie, Maurice Zauderer, CEO, Vaccinex Inc, Michela Gallagher, Founder, AgeneBio Inc., Michelle Sidor, Director, Neuroscience, Alchemab Therapeutics Ltd, Natasha Penner, Senior Director and Head of Clinical Pharmacology, Neurology Business, Eisai, Nathan Hatcher, Senior Principal Scientist, Merck and Co, Neelroop Parikshak, Associate Director, Neuroscience and Ophthalmology Genetics, Regeneron Pharmaceuticals Inc, Neil Cashman, Chief Scientific Officer and Co-Founder, ProMIS Neurosciences, Niall Mortimer, Senior Data Scientist, Computational Biology, Eisai, Nicola Corbett, Associate Principal Scientist, MSD, Ornit Chiba-Falek, Co-Founder, CLAIRIgene, Pallavi Sachdev, Executive Director, Eisai, Patrick Downey, Senior Director, UCB S.A., Paul Ashton, President and Chief Executive Officer, Inflammasome Therapeutics, Paul Song, Chief Scientific Officer, Genequantum Healthcare, Peter Reinhardt, Principal Research Scientist, Abbvie, Rouba Kozak, Global Biomarker Diagnostic Lead, Neuroscience, Novartis AG, Samantha Hutten, Director, Discovery and Translational Research, The Michael J. Fox Foundation for Parkinson's Research, Simon Dujardin, Principal Scientist, Sanofi, Simonne Longerich, Director, Early Discovery Genetics, Merck and Co, Steve Piccoli, Head Clincal Biomarkers, Sun Pharma, Suganya Selvarajah, Director of Biology, CNS Diseases, Research and Development, Attralus Inc, Thierry Bussiere, Senior Director, Biogen, Valerie Daggett, CEO, Founder, AltPep Corporation